R(+) pramipexole as a mitochondrially focused neuroprotectant: Initial early phase studies in ALS

References

• Barber S. C., Mead R. J., Shaw P. J. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 2006; 1762: 1051–67
   PubMed Web of Science ®Google Scholar
• Carri M. T., Ferri A., Cozzolino M., Calabrese L., Rotilio G. Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals. Brain Res Bull 2003; 61: 365–74
   PubMed Web of Science ®Google Scholar
• Koh S. H., Lee S. M., Kim H. Y., Lee K. Y., Lee Y. J., Kim H. T., et al. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett 2006; 395: 103–7
   PubMed Web of Science ®Google Scholar
• Mahoney D. J., Kaczor J. J., Bourgeois J., Yasuda N., Tarnopolsky M. A. Oxidative stress and antioxidant enzyme up‐regulation in SOD1‐G93A mouse skeletal muscle. Muscle Nerve 2006; 33: 809–16
   PubMed Web of Science ®Google Scholar
• Niebroj‐Dobosz I., Dziewulska D., Kwiecinski H. Oxidative damage to proteins in the spinal cord in amyotrophic lateral sclerosis (ALS). Folia Neuropathol 2004; 42: 151–6
   PubMedGoogle Scholar
• Simpson E. P., Henry Y. K., Henkel J. S., Smith R. G., Appel S. H. Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 2004; 62: 1758–65
   PubMed Web of Science ®Google Scholar
• Sohmiya M., Tanaka M., Suzuki Y., Tanino Y., Okamoto K., Yamamoto Y. An increase of oxidized coenzyme Q‐10 occurs in the plasma of sporadic ALS patients. J Neurol Sci 2005; 228: 49–53
   PubMed Web of Science ®Google Scholar
• Casoni F., Basso M., Massignan T., Gianazza E., Cheroni C., Salmona M., et al. Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem 2005; 280: 16295–304
   PubMed Web of Science ®Google Scholar
• Martin L. J., Liu Z., Chen K., Price A. C., Pan Y., Swaby J. A., et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superoxide dismutase‐1 transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp Neurol 2007; 500: 20–46
   PubMed Web of Science ®Google Scholar
• Danzeisen R., Schwalenstoecker B., Gillardon F., Buerger E., Krzykalla V., Klinder K., et al. Targeted antioxidative and neuroprotective properties of the dopamine agonist pramipexole and its non‐dopaminergic enantiomer SND919CL2x [(+)2‐amino‐4,5,6,7‐tetrahydro‐6‐Lpropylamino‐benzathiazole dihydrochloride]. J Pharmacol Exp Ther 2006; 316: 189–99
   PubMed Web of Science ®Google Scholar
• Abramova N. A., Cassarino D. S., Khan S. M., Painter T. W., Bennett J. P Jr. Inhibition by R(+) or S(−) pramipexole of caspase activation and cell death induced by methylpyridinium ion or beta‐amyloid peptide in SH‐SY5Y neuroblastoma. J Neurosci Res 2002; 67: 494–500
   PubMed Web of Science ®Google Scholar
• Moore D. H II., Miller R. G. Improving efficiency of ALS clinical trials using lead‐in designs. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5((Suppl 1))57–60
   PubMedGoogle Scholar
• Brooks B. R. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial ‘clinical limits of amyotrophic lateral sclerosis’ workshop contributors. J Neurol Sci 1994; 124((Suppl))96–107
   PubMed Web of Science ®Google Scholar
• Swash M., de Carvalho M. The Neurophysiological Index in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5((Suppl 1))108–10
   PubMedGoogle Scholar
• Cedarbaum J. M., Stambler N., Malta E., Fuller C., Hilt D., Thurmond B., et al. The ALSFRS‐R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999; 169: 13–21
   PubMed Web of Science ®Google Scholar
• Gordon P. H., Miller R. G., Moore D. H. ALSFRS‐R. Amyotroph Lateral Scler Other Motor Neuron Disord 2004; 5((Suppl 1))90–3
   PubMed Web of Science ®Google Scholar
• Traynor B. J., Zhang H., Shefner J. M., Schoenfeld D., Cudkowicz M. E. NEALS Consortium. Functional outcome measures as clinical trial endpoints in ALS. Neurology 2004; 63: 1933–5
   PubMed Web of Science ®Google Scholar
• Shefner J. M., Cudkowicz M. E., Schoenfeld D., Conrad T., Taft J., Chilton M., et al. A clinical trial of creatine in ALS. Neurology 2004; 63: 1656–61
   PubMed Web of Science ®Google Scholar
• Wong S. K. A 384‐well cell‐based phospho‐ERK assay for dopamine D2 and D3 receptors. Anal Biochem 2004; 333: 265–72
   PubMed Web of Science ®Google Scholar